Loading company…
Oblenio Bio develops therapies for refractory autoimmune diseases, including its LBL-051 T-cell engager.
Oblenio Bio develops LBL-051, a tri-specific antibody designed to target BCMA, CD19, and CD3 for autoimmune diseases. Founded in 2024 in Lexington, US, the company is led by CEO Samantha Truex. It raised USD 62.00 mn in Series B funding in June 2026, led by Pfizer Venture Investments with Aditum Bio, Deep Track Capital, and GV participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in